Application of monoform megamonas in preparation of composition for degrading phytic acid

Abstract

The invention relates to the field of probiotics, in particular to application of monoform megamonas in preparation of a composition for degrading phytic acid. The invention discovers that the Megamonas simplex DSM 19343 has a better degradation effect on phytic acid in vitro and in vivo, and can be used as a probiotic to degrade phytic acid in intestinal tracts into acetic acid and propionic acid, so that the intestinal mucosal barrier is protected, and the intestinal absorption of nutrient substances such as mineral substances and the like is indirectly promoted.

Description

Technical Field

[0001] The present invention relates to the field of probiotics, and specifically, to the use of Megamonas funiformis in the preparation of a composition for degrading phytic acid. Background Art

[0002] Phytic acid is the main phosphorus storage form in almost all whole grains, legumes, and oilseeds, and is ubiquitous in common legumes, grains, nuts, and root vegetables. Phytic acid forms complexes with mineral ions in the body, and the first step in mineral absorption requires these minerals to remain in an ionic state. Since humans lack phytase, phytic acid is difficult to be decomposed and absorbed by the intestine. Therefore, when phytic acid binds to minerals such as iron, zinc, calcium, magnesium, and manganese, it will reduce the absorption efficiency of these minerals, and may further lead to a decrease in the body's mineral levels. In many developing countries, the diet is mainly based on grains and legumes, so the intake of phytic acid is significantly increased compared with developed countries.

[0003] Short-chain fatty acids (SCFAs) are the end products of the fermentation of indigestible carbohydrates in the small intestine by gut microbiota, mainly including acetic acid and propionic acid. Studies have shown that acetate may be involved in the process of regulating other gut microbiota, especially it can induce the body's immune response against harmful bacteria. In addition, SCFAs also have the effects of protecting the intestinal mucosal barrier and improving intestinal function.

[0004] In recent years, the role of gut microbiota has attracted more and more attention from researchers, especially the interaction between gut microbiota. At present, there have been reports on regulating intestinal function by taking probiotics or prebiotics and other nutrients. However, most of the existing probiotics are developed based on the diet structure and gut microbiota function of European and American populations. Therefore, there is a need in this field to develop a new probiotic that is more suitable for Asian populations, can alleviate the damage to mineral absorption caused by high levels of phytic acid in the diet, and degrade phytic acid into acetic acid and propionic acid to protect the intestinal mucosal barrier. Summary of the Invention

[0005] The present invention notes that Megamonas funiformis has not been reported as a major species in gut microbiome studies targeting European and American populations, but has been found in studies involving Asian populations, indicating that this bacterium may be a characteristic of Asian populations. However, little is known about its function at present.

[0006] The present invention first provides the use of Megamonas funiformis DSM 19343 in the preparation of a composition for degrading phytic acid.

[0007] The present invention discovers that Megamonas funiformis DSM 19343 has better degradation effects on phytic acid both in vitro and in vivo. It can be used as a probiotic to degrade phytic acid in the intestine into acetic acid and propionic acid, which is beneficial to protecting the intestinal mucosal barrier and has an indirect promoting effect on the intestinal absorption of nutrients such as minerals. BRIEF DESCRIPTION OF THE DRAWINGS

[0008] In order to more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the following will briefly introduce the drawings required for the description of the specific embodiments or the prior art. Obviously, the drawings in the following description are some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can be obtained based on these drawings.

[0009] Figure 1 It shows the change in the phytic acid content in the supernatant of the Megamonas funiformis culture medium in the phytic acid addition group in the embodiment of the present invention.

[0010] Figure 2 It shows the changes in the acetic acid (left) and butyric acid (right) contents in the supernatants of the control group and the phytic acid addition group of Megamonas funiformis culture medium in the embodiment of the present invention.

[0011] Figure 3 It shows the changes in the serum phytic acid contents of the control group (NC), the phytic acid gavage group (PA), and the phytic acid and Megamonas funiformis gavage group (PA_MF) mice in the embodiment of the present invention.

[0012] Figure 4 It shows the changes in the serum calcium, copper, iron, magnesium, manganese, and zinc contents of the control group (NC), the phytic acid gavage group (PA), and the phytic acid and Megamonas funiformis gavage group (PA_MF) mice in the embodiment of the present invention.

[0013] Figure 5 It shows the changes in the acetic acid and butyric acid contents in the ileocecal contents of the control group (NC), the phytic acid gavage group (PA), and the phytic acid and Megamonas funiformis gavage group (PA_MF) mice in the embodiment of the present invention. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0014] The following will elaborate on the specific embodiments of the present invention. It should be understood that the specific embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention. Those skilled in the art can make various modifications and changes to the present invention without departing from the scope or spirit of the present invention. For example, the features described or illustrated as part of one embodiment can be used in another embodiment to produce a further embodiment.

[0015] Unless otherwise specified, the meanings of all terms (including technical and scientific terms) used to disclose the present invention are the same as those commonly understood by those of ordinary skill in the art to which the present invention pertains. Through further guidance, the following definitions are used to better understand the teachings of the present invention. The terms used in the description of the present invention herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention.

[0016] As used herein, the alternative ranges of the terms "and / or", "or / and", and "and / or" include any one of two or more related listed items, and also include any and all combinations of the related listed items. The said any and all combinations include combinations of any two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, this technical solution undoubtedly includes the technical solution connected by "logical AND", and also undoubtedly includes the technical solution connected by "logical OR". For example, "A and / or B" includes three parallel solutions: A, B, and A + B. Another example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, includes combinations of any two or any three of A, B, C, and D, and also includes the four-item combination of A, B, C, and D (that is, the technical solution connected by "logical AND").

[0017] The terms "comprising", "including", and "containing" used in the present invention are synonyms, which are inclusive or open-ended and do not exclude additional, unrecited members, elements, or method steps.

[0018] In the present invention, the numerical ranges indicated by endpoints include all the numerical values and fractions contained within the range, as well as the recited endpoints.

[0019] Regarding the concentration values involved in the present invention, their meanings include fluctuations within a certain range. For example, it can fluctuate within the corresponding precision range. For example, for 2%, a fluctuation within the range of ±0.1% is allowed. For larger numerical values or those that do not require overly precise control, a greater fluctuation is also allowed for their meanings. For example, for 100 mM, fluctuations within the ranges of ±1%, ±2%, ±5%, etc. are allowed. Regarding the molecular weight, a fluctuation of ±10% is allowed for its meaning.

[0020] In the present invention, regarding descriptions such as "a plurality of" and "a variety of", unless otherwise specified, it means greater than or equal to 2 in quantity.

[0021] In the present invention, among the technical features described in an open-ended manner, there are included both a closed technical solution composed of the listed features and an open technical solution containing the listed features.

[0022] In the present invention, "preferred", "better", "more preferred", and "preferably" are only used to describe embodiments or examples with better effects, and it should be understood that they do not constitute a limitation to the protection scope of the present invention.

[0023] In the present invention, "optionally", "optional", "option", "optionally", "optional", "option" mean that it can be either present or absent, that is, it refers to any one selected from two parallel options of "present" or "absent". If there are multiple "optionally" or "optional" in a technical solution, without special instructions and without contradictions or mutual constraints, each "optionally" or "optional" is independent.

[0024] The present invention first provides the use of Megamonas funiformis DSM 19343 in the preparation of a composition for degrading phytic acid.

[0025] In some specific embodiments, the composition is used to degrade the phytic acid content in a subject.

[0026] In some specific embodiments, the composition is used to degrade the phytic acid content in vitro. That is, the composition is used to degrade the phytic acid content in vitro for non-therapeutic purposes.

[0027] In some embodiments, the composition is used to increase the content of acetic acid and / or propionic acid in a subject.

[0028] In some embodiments, the composition is used to increase the content of minerals in a subject. That is, the composition is used to enhance the intestinal absorption of minerals in a subject.

[0029] In some embodiments, the minerals include one or more of copper, iron, zinc, manganese, magnesium, and calcium.

[0030] In some embodiments, the "in vivo" includes the intestine and blood.

[0031] In some embodiments, the intestine includes the large intestine.

[0032] Since the production and absorption of short-chain fatty acids mainly occur in the large intestine (colon and rectum), the present invention mainly measured the content changes of acetic acid and propionic acid in the large intestine (such as the ileocecal region) in subsequent experiments, but this does not limit the scope of protection of the present invention. Based on subsequent in vivo and in vitro experiments, it is not difficult to judge that Megamonas uniformis DSM 19343 can reduce the phytic acid content in the intestine and blood, and increase the content of acetic acid and propionic acid, not limited to the location of the large intestine (such as the ileocecal region).

[0033] In some embodiments, the composition is used to increase the content of acetic acid and / or propionic acid in the intestine of a subject.

[0034] In some embodiments, the composition is used to reduce the phytic acid content in the intestine and blood of a subject.

[0035] In some embodiments, the composition is used to increase the mineral content in the intestine and blood of a subject.

[0036] In some embodiments, the composition is used to prevent or treat diseases in any of the following aspects: 1) diseases related to excessive phytic acid content in the body; 2) diseases related to too low content of acetic acid and / or propionic acid in the body; 3) diseases related to too low absorption of minerals in the body.

[0037] In some embodiments, the diseases include one or more of mineral deficiency, osteoporosis, decreased immune function, indigestion, intestinal inflammation, impaired intestinal barrier function, and intestinal flora imbalance.

[0038] In some embodiments, the subject has a high phytic acid food diet habit. For example, the subject's diet is mainly based on grains (especially untreated whole grains), legumes, nuts, and seeds.

[0039] In some embodiments, the subject includes humans and other animals other than humans. The other animals mentioned here other than humans can be primates such as monkeys, orangutans, gibbons, and gorillas; domestic animals such as pigs, cows, sheep, horses, and camels; common pets such as cats, dogs, rabbits, and mice; poultry such as chickens, ducks, geese, and quails; and so on.

[0040] In some embodiments, the subject includes mammals.

[0041] In some embodiments, the composition is a food composition, a health composition, a pharmaceutical composition, or a feed composition.

[0042] The present invention does not particularly limit the type of food composition, which can be in the form of oral preparations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, etc., or can be added to common foods such as sugars, biscuits, chewing gums, ice creams, noodles, breads, beverages, etc.

[0043] The food composition of the present invention can be prepared by appropriately using one or more of fillers, extenders, binders, wetting agents, disintegrants, sweeteners, fragrances, preservatives, surfactants, lubricants, excipients, etc. according to the different forms by conventional methods.

[0044] The health composition of the present invention can be in dosage forms such as capsules, powders, liquids, tablets, granules, etc. In some specific embodiments, according to the needs of the dosage form, one or more of protectants (for maintaining the activity and stability of probiotics), prebiotics (also known as prebiotics, providing nutrients required for the growth of probiotics in the intestine), fillers, diluents, stabilizers, preservatives, antioxidants, flavoring agents, etc. can be appropriately used in the health composition for preparation.

[0045] The pharmaceutical composition of the present invention can be administered orally (e.g., taken or inhaled) or parenterally (e.g., rectal administration).

[0046] The pharmaceutical composition of the present invention can be formulated into tablets, capsules, granules, fine subtilae, powders, sublingual tablets, suppositories, emulsions, suspensions, syrups, etc. according to the different administration routes. The pharmaceutical compositions of the above various forms according to the present invention can utilize pharmaceutical carriers commonly used in each dosage form and be manufactured by known techniques. Examples of pharmaceutically acceptable carriers include excipients, binders, disintegrants, lubricants, preservatives, antioxidants, isotonic agents, buffers, coating agents, sweeteners, solubilizers, bases, dispersants, wetting agents, suspending agents, stabilizers, colorants, etc.

[0047] In some embodiments, the feed composition can be carbohydrate feed, protein feed, green feed, mineral feed, etc. At the same time, those skilled in the art can confirm the specific components of the above feeds in combination with common sense. For example, carbohydrate feed can contain corn, bran, wheat, barley, sorghum, rice bran, etc.

[0048] The embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and not to limit the scope of the present invention. For the experimental methods without specific conditions in the following examples, the guidance given in the present invention is preferably referred to, and it can also be carried out according to the experimental manuals or conventional conditions in the art, or other experimental methods known in the art, or according to the conditions recommended by the manufacturer.

[0049] The Megamonas funiformis DSM 19343 mentioned in the present invention can be obtained through commercial channels. Hereinafter, it is simply referred to as Megamonas funiformis DSM 19343.

[0050] In the following specific examples, regarding the measurement parameters of raw material components, without special instructions, there may be slight deviations within the weighing accuracy range. Regarding temperature and time parameters, acceptable deviations caused by instrument testing accuracy or operation accuracy are allowed.

[0051] Examples

[0052] (1) Preparation of the liquid medium for Megamonas funiformis DSM 19343:

[0053] Weigh 57.5 g of minced meat carbohydrate basal broth powder (Mingzhou Biology) into 1 L of distilled water or deionized water, heat to boiling and keep boiling for more than 1 min, dispense into test tubes, add an appropriate amount of KDM150-1 (chopped meat beef granules, about 1 / 3 height of the liquid) to the test tubes, sterilize at 121 °C under high pressure for 30 mins, cool to below 50 °C, under aseptic operation, add 1 vial of KDM168 hemin, 1 vial of KDM153 vitamin K1 or 0.5 vial of KDM166 vitamin K3 per 100 mL, mix well, dispense into 50 mL sterile centrifuge tubes, place in an anaerobic zone to remove oxygen for 24 h, and set aside.

[0054] (2) Preparation of the 10 mg / mL phytic acid stock solution:

[0055] Weigh 0.1 g of phytic acid powder and dissolve it in 10 mL of deionized water, then filter and sterilize it through a 0.22 μm filter, and set aside.

[0056] (3) Resuscitation of Megamonas funiformis DSM 19343:

[0057] After rewarming the glycerol bacteria from -80 °C to room temperature, pick a loop of the bacterial liquid and streak it on a Columbia blood agar plate in four zones, and place it under its optimal conditions at 37 °C for anaerobic culture for 48 h. The culture result shows that the colonies are milky white, flat, with irregular wavy edges, and low water content, and the diameter is about 3 - 4 mm.

[0058] (4) Activation of Megamonas funiformis DSM 19343:

[0059] Pick a single colony on the Columbia blood agar plate after resuscitation and streak it again in four zones, and place it under its optimal conditions at 37 °C for anaerobic culture for 48 h.

[0060] (5) Enrichment of Megamonas funiformis DSM 19343:

[0061] Pick a single colony on the activated Columbia blood agar plate and place it in a pre-oxygen-depleted liquid medium. Incubate it at its optimal condition of 37°C under anaerobic conditions for 48 hours.

[0062] (6) In vitro verification of the production of acetic acid and propionic acid by Megamonas hydrogenitolerans DSM 19343 during phytic acid degradation:

[0063] Dilute the bacterial liquid of Megamonas hydrogenitolerans DSM 19343 after enrichment 1:100 into several tubes containing 10 mL of liquid medium. Divide it into two groups. Add 50 μL of distilled water to the control group and 50 μL of a 10 mg / mL phytic acid solution to the experimental group. After mixing, incubate it at its optimal condition of 37°C under anaerobic conditions for 4 hours, 8 hours, and 24 hours until its lag phase, logarithmic growth phase, and stationary phase respectively. Then, take 5 mL of the bacterial liquid, centrifuge it at 3000 g for 10 minutes at 4°C, aspirate the supernatant into a 1.5 mL EP tube, quickly freeze it in liquid nitrogen, and store it in a -80°C refrigerator for subsequent detection of phytic acid, acetic acid, and propionic acid contents.

[0064] (7) In vivo verification of the promotion of trace element absorption by the production of acetic acid and propionic acid during phytic acid degradation by Megamonas hydrogenitolerans DSM 19343:

[0065] Dilute the bacterial liquid of Megamonas hydrogenitolerans DSM 19343 after enrichment 1:100 into 10 mL of liquid medium and incubate it at 37°C under anaerobic conditions until OD600nm = 1.0 (1X10 9 cfu / mL) for standby. Randomly divide male C57BL / 6J mice at 6 weeks of age into cages of 4 mice each. Keep a strict 12-hour light cycle, allow free access to food and water, and feed them a normal high-mineral diet (AIN-93G diet, Shuangshi experimental animal feed) for one week of acclimation. Randomly divide the above mice into three groups. Mice in the blank group are gavaged with 0.2 mL of 0.85% NaCl every day, mice in the control group are gavaged with 0.2 mL of phytic acid at 0.2 mg / g of mouse body weight every day, and mice in the experimental group are gavaged with 0.2 mL of phytic acid at 0.2 mg / g of mouse body weight and 1*10 9 CFU / mL of Megamonas hydrogenitolerans DSM 19343 every day for 2 weeks. At the end of the second week, fast the mice for 12 hours, then euthanize the mice and collect eyeball blood and ileocecal contents. Place the blood sample in a 1.5 mL EP tube for at least 3 hours, then centrifuge it at 4000 rpm for 10 minutes at 4°C, collect the serum into a 1.5 mL EP tube, and store it in a -80°C refrigerator for determination of phytic acid, copper, iron, magnesium, zinc, and calcium element concentrations. After blood collection, take the ileocecal contents into a 1.5 mL EP tube and store it in a -80°C refrigerator for determination of acetic acid and propionic acid contents.

[0066] (8) The phytate content in the supernatant of the bacterial solution and serum was detected using a phytate detection kit (BC5845, Solarbio):

[0067] Step 1: Add 100 μL of serum or culture supernatant to 1 mL of Extract I, and shake well at 25 °C for 2 hours. Then, centrifuge at 10,000 g for 10 minutes at 4 °C, and collect 0.8 mL of the supernatant.

[0068] Step 2: Slowly add 0.15 mL of Extract II, mix gently, and centrifuge at 10,000 g for 10 minutes at 4 °C. Then, collect 120 μL of the supernatant.

[0069] Step 3: Add 50 μL of Reagent II, incubate in a water bath at 37 °C for 30 min, then add 50 μL of the working solution, and let it stand at 25 °C for 10 min. Measure OD700 (detection). Take 120 μL of the supernatant from Step 2, add 50 μL of Reagent I, and measure at OD700 (control) according to the steps of Step 3. Take 120 μL of a 250 nmol / mL standard phytate solution, and measure at OD700 (standard) according to the same steps of Step 3. Take 120 μL of Reagent I, and measure at OD700 (blank) according to the steps of Step 3. Each serum sample requires a corresponding control tube. The concentration of phytate in the serum or culture supernatant can be calculated using the following formula:

[0070] ΔA measure =A measure -A control

[0071] ΔA standard =A standard -A blank

[0072]

[0073] C standard : The concentration of the phytate standard in this kit is 250 nmol / mL; V supernatant : The volume of the supernatant added in Step 2 is 120 μL; V solution II : The volume of Extract II in Step 2, which is 0.15 mL in this method; V solution I : The volume of Extract I in Step 1, which is 1 mL in this method; V total : The total liquid volume after adding the working solution, which is 0.1 mL in this method.

[0074] (9) The concentrations of acetic acid and propionic acid in the ileocecal content or culture supernatant were determined by gas chromatography - mass spectrometry (GC - MS 7890A - 5975C, Agilent Technologies, USA).

[0075] For the ileocecal contents, the following steps are applied:

[0076] Step 1: Add 1 mL of pure water to 25 mg of ileocecal sample and vortex for 10 seconds;

[0077] Step 2: Add steel beads, process with a 40 Hz grinder for 4 minutes, and then ultrasonically treat in an ice-water bath for 5 minutes (repeat 3 times);

[0078] Step 3: Centrifuge the sample at 5000 rpm at 4 °C for 20 minutes;

[0079] Step 4: Transfer 0.8 mL of the supernatant to a new 2 mL EP tube;

[0080] Step 5: Add 0.1 mL of 50% H2SO4 and 0.8 mL of internal standard solution (200 μg / mL 2-ethylbutyric acid, with MTBE as the solvent) (214353, Fisher), vortex for 10 seconds in an ice-water bath, oscillate for 10 minutes, and ultrasonicate for 10 minutes;

[0081] Step 6: Centrifuge at 10000 rpm at 4 °C for 15 minutes, let stand at -20 °C for 30 minutes, and take 100 μL of the supernatant for GC-MS analysis.

[0082] For the culture supernatant sample, the following steps are applied:

[0083] Step 1: Add 0.05 mL of 50% H2SO4 and 0.2 mL of internal standard solution to 100 μL of the sample, vortex for 30 seconds, oscillate for 10 minutes, and ultrasonicate in an ice-water bath for 10 minutes;

[0084] Step 2: Centrifuge the sample at 10000 rpm at 4 °C for 15 minutes;

[0085] Step 3: Let stand at -20 °C for 30 minutes, and take 100 μL of the supernatant for GC-MS analysis.

[0086] (10) Inductively coupled plasma mass spectrometry (ICP-MS NexION 1000G, PerkinElmer, USA) was used to evaluate the levels of copper (Cu), iron (Fe), zinc (Zn), manganese (Mn), magnesium (Mg), and calcium (Ca) in mouse serum. Add 100 μL of serum to a polytetrafluoroethylene digestion container, add 0.5 mL of 68% HNO3, add reagents to another polytetrafluoroethylene digestion container as a blank control, and tighten the digestion container after the bubbles completely disappear. Place the digestion container in a microwave digestion system and start digestion according to the digestion protocol. After cooling, transfer the digested solution to a 10 mL volumetric flask and dilute to 5 mL with ddH2O. After filtering the diluted sample through a 0.22 μm membrane, it was detected by ICP-MS.

[0087] (11) Experimental results:

[0088] In vitro experimental results showed that with the change of growth state, the concentration of phytic acid in the experimental group decreased significantly ( Figure 1 ), while the contents of acetic acid and propionic acid increased significantly ( Figure 2 ).

[0089] In vivo experimental results showed that the average serum phytic acid concentration of mice in the control group (phytic acid group, Figure 3 corresponding to the PA group) was the highest, followed by the experimental group (phytic acid + Megamonas funiformis DSM 19343 group, Figure 3 corresponding to the PA_MF group), and the lowest was the blank group (saline group, Figure 3 corresponding to the NC group). And the contents of various trace elements such as copper, iron, zinc, manganese, magnesium and calcium in the serum were the highest in the blank group (saline group, Figure 4 corresponding to the NC group), followed by the experimental group (phytic acid + Megamonas funiformis DSM19343 group, Figure 4 corresponding to the PA_MF group), and the lowest was the control group (phytic acid group, Figure 4 corresponding to the PA group). In the ileocecal contents, the order of the average contents of acetic acid and propionic acid from high to low in the mouse groups was the experimental group (phytic acid + Megamonas funiformis DSM19343 group, Figure 5 corresponding to the PA_MF group), the blank group (saline group, Figure 5 corresponding to the NC group), and the control group (phytic acid group, Figure 5 corresponding to the PA group).

[0090] The above results indicate that Megamonas funiformis DSM 19343 can produce acetic acid and propionic acid by degrading phytic acid both in vivo and in vitro, thereby indirectly promoting the absorption of trace elements.

[0091] The above-described embodiments only represent several implementation manners of the present invention. The description is relatively specific and detailed, but it should not be construed as a limitation on the scope of the invention patent. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present invention, several deformations and improvements can still be made, and these all belong to the protection scope of the present invention.

Claims

1. Use of Megamonas funiformis DSM 19343 in the preparation of a composition for degrading phytic acid.

2. The use according to claim 1, wherein: The composition is used to degrade phytic acid levels in a subject.

3. The use according to claim 1 or 2, wherein: The composition is used to increase the level of acetic acid and / or propionic acid in a subject.

4. The use according to claim 1, wherein: The composition is used to increase the mineral content in a subject.

5. The use according to claim 4, wherein: The minerals include one or more of copper, iron, zinc, manganese, magnesium and calcium.

6. The use according to any one of claims 2 to 5, wherein: The body includes the intestine and blood.

7. The use according to claim 6, wherein: The intestinal tract includes the large intestine.

8. The use according to any one of claims 1 to 7, wherein: The composition is used to prevent or treat any of the following diseases: 1) Diseases related to excessive phytic acid levels in the body; 2) Diseases related to low levels of acetic acid and / or propionic acid in the body; 3) Diseases related to low absorption of minerals in the body; Preferably, the disease includes one or more of mineral deficiency, osteoporosis, decreased immune function, indigestion, intestinal inflammation, impaired intestinal barrier function, and intestinal flora imbalance.

9. The use according to any one of claims 2 to 8, wherein: The subject has a high-phytic acid food dietary habit; preferably, the subject includes humans and other animals except humans.

10. The use according to any one of claims 1 to 9, wherein: The composition is a food composition, a health care composition, a pharmaceutical composition, or a feed composition.

Images